awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33421680-E9675443-4091-4ED1-8957-B8B776B89351
Q33421680-E9675443-4091-4ED1-8957-B8B776B89351
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33421680-E9675443-4091-4ED1-8957-B8B776B89351
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
P2860
Q33421680-E9675443-4091-4ED1-8957-B8B776B89351
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33421680-E9675443-4091-4ED1-8957-B8B776B89351
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6270fcb212900cebcc41ad25348d5d6dede30662
P2860
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.